SECURITIES AND EXCHANGE COMMISSION
SCHEDULE TO
(Rule 14d-100)
Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1) of
the Securities Exchange Act of 1934
(Amendment No. 7)
RESPIRONICS, INC.
(Name of Subject Company (Issuer))
MOONLIGHT MERGER SUB, INC.
a wholly owned subsidiary of
PHILIPS HOLDING USA INC.
a wholly owned subsidiary of
KONINKLIJKE PHILIPS ELECTRONICS N.V.
(Names of Filing Persons (Offerors))
Common Stock, par value $ 0.01 per share,
and associated common stock acquisition rights
(Title of Class of Securities)
761230101
(CUSIP Number of Class of Securities)
Joseph E. Innamorati, Esq.
Moonlight Merger Sub, Inc.
1251 Avenue of the Americas
20th Floor
New York, NY 10020-1104
(212) 536-0641
(Name, address and telephone number of person authorized to receive notices and communications
on behalf of filing persons)
With a copy to:
Neil T. Anderson
Matthew G. Hurd
Sullivan & Cromwell LLP
125 Broad Street
New York, New York 10004
Telephone: (212) 558-4000
CALCULATION OF FILING FEE
| |
|
|
|
|
|
| |
| |
Transaction Valuation* |
|
|
Amount of Filing Fee |
|
| |
$4,899,365,658 |
|
|
$192,545.07 |
|
| |
|
|
|
| * |
|
Estimated for purposes of calculating the amount of the filing fee only. This calculation
assumes the purchase of 74,232,813 outstanding shares of common stock, par value $0.01 per
share, including the associated common stock acquisition rights (such rights, together with
such shares of the Company’s common stock, the “Shares”) issued under the Rights Agreement,
dated June 28, 1996, between Respironics, Inc. and Mellon Investor Services LLC, as amended,
for a price of $66.00 per Share. The calculation of the filing fee is based on the Company’s
representation of its capitalization as of December 18, 2007. |
| þ |
|
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify
the filing with which the offsetting fee was previously paid. Identify the previous filing
by registration statement number or the Form or Schedule and the date of its filing. |
| |
|
|
|
|
|
|
|
|
Amount Previously Paid:
|
|
$ |
192,545.07 |
|
|
Filing Party:
|
|
Moonlight Merger Sub, Inc. |
Form or Registration No.:
|
|
Schedule TO
|
|
Date Filed:
|
|
January 3, 2008 |
| o |
|
Check the box if the filing relates solely to preliminary communications made before the
commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
| |
þ |
|
third-party tender offer subject to Rule 14d-1. |
| |
| |
o |
|
issuer tender offer subject to Rule 13e-4. |
| |
| |
o |
|
going-private transaction subject to Rule 13e-3. |
| |
| |
o |
|
amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender
offer. o
TABLE OF CONTENTS
This Amendment No. 7 (this “Amendment”) amends and supplements Items 11 and 12 in the Tender
Offer Statement on Schedule TO, filed on January 3, 2008 (the “Schedule TO”) with the Securities
and Exchange Commission by Moonlight Merger Sub, Inc., a Delaware corporation, as amended on
January 16, 2008, January 28, 2008, January 31, 2008, February 4, 2008, February 6, 2008 and
February 25, 2008.
Except as otherwise indicated in this Amendment, the information set forth in the Schedule TO
remains unchanged. Capitalized terms used but not defined herein have the meanings ascribed to them
in the Schedule TO.
Item 11. Additional Information.
(a)(2) and (a)(3) The information set forth in the section of the Offer to Purchase entitled
“Certain Legal Matters—European Union Antitrust Compliance” is hereby amended and
supplemented by adding the following at the end thereof:
On March 5, 2008, Royal Philips and the Company issued a joint press release
announcing that approval under the EC Merger Regulation had been obtained as of such
date. A copy of the joint press release is filed as Exhibit (a)(2)(G) to the
Schedule TO and is incorporated herein by reference.
Item 12. Exhibits.
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following
exhibit:
| |
|
|
| Exhibit No. |
|
Exhibit Name |
| |
(a)(2)(G)
|
|
Joint Press Release, issued by Royal Philips and the Company, dated March 5, 2008. |